

**MARKED-UP CLAIM AMENDMENTS**

1. (Amended) Method of treating an underlying cause of a pathological [conditions]  
condition characterized by an increased IL-1 and/or TNF- $\alpha$  level which comprises administering to a subject having such condition a therapeutically effective amount of at least one member selected from [the] a first group consisting of diacerein and rhein, in a pharmaceutical dosage form.

11. (Amended) Method of treating an underlying cause of an inflammatory [and] and/or  
autoimmune [conditions] condition characterized by an increased IL-1 [and or] and/or TNF- $\alpha$  level which comprises modifying the production or action of proinflammatory cytokines, including said IL-1 and/or TNF- $\alpha$ , by administering to a subject having such condition a therapeutically effective amount of at least one member selected from [the] a first group consisting of diacerein and rhein, in a pharmaceutical dosage form.

EX A